| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Goserelin is a synthetic decapeptide analogue of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary and activates them. Goserelin inhibits pituitary gonadotropin secretion, which lowers testosterone (in males) and estradiol (in females) levels when taken for an extended period of time. Regression of sex hormone-sensitive tumors and reduction of sex organ size and function may occur from the administration of this agent in a depot formulation.
| Targets |
GnRH
|
|---|---|
| ln Vitro |
Goserelin (1 nM-1 mM; 48-72 hours) promotes expression in EOC cells [1]. Goserelin (100 μM; 24-72 hours) regulates the expression of human liver cancer-related genes in SKOV3-ip cells [1]. (100 μM; 24-72 hours) promotes EOC cell inflammation by upregulating FOXO1 through PI3K/AKT signaling [1]. Apoptosis analysis [1] Cell Line: SKOV3 cells, SKOV3-ip cells, A2780 cells (human EOC cell line) Concentration: 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM, 1 mM Incubation time : 48 hours, 72 hours results: significantly increased the total apoptosis rate of SKOV3-ip, SKOV3 and A2780 cells. Western Blot Analysis[1] Cell lines: SKOV3 cells, SKOV3-ip cells, A2780 cells (human EOC cell line) Concentration: 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM, 1 mM Incubation time: Results at 48 hours and 72 hours: At 100 μM, the expression of cleaved-caspase-3 and cleaved-PARP increased significantly. RT-PCR[1] Cell line: SKOV3-ip Cell concentration: 100 μM Incubation time: 24 hours, 48 hours, 72 hours Results: Expression of human apoptosis-related genes is regulated
|
| ln Vivo |
Goserelin acetate (100 μg; subcutaneous injection; daily; for 19 days) significantly increases the proportion of anode cells in subcutaneous xenograft tumors [1]. Animal model: Five-week-old specific pathogen-free (SPF) female nude mice (18-20 g), subcutaneous xenograft tumor model [1] Dosage: 100 µg/mouse Administration: subcutaneous injection, daily, for 19 days Results : Significantly increases the proportion of apoptotic cells in subcutaneous xenograft tumors
|
| Cell Assay |
Cell Line: SKOV3 cells, SKOV3-ip cells, A2780 cells (human EOC cell lines)
Concentration: 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM, 1 mM Incubation Time: 48 hours, 72 hours Result: Significantly increased the total apoptosis rate of SKOV3-ip, SKOV3 and A2780 cells |
| Animal Protocol |
Five-week-old specific-pathogen free (SPF) female nude mice (18-20 g), subcutaneous xenograft tumor model
100 µg/mice Subcutaneous injection, daily, for 19 days |
| References |
|
| Molecular Formula |
C61H88N18O16
|
|---|---|
| Molecular Weight |
1329.485
|
| Exact Mass |
1328.66
|
| Elemental Analysis |
C, 55.11; H, 6.67; N, 18.96; O, 19.25
|
| CAS # |
145781-92-6
|
| Related CAS # |
Goserelin; 65807-02-5
|
| Appearance |
White to off-white solid powder
|
| SMILES |
CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6.CC(=O)O
|
| InChi Key |
IKDXDQDKCZPQSZ-JHYYTBFNSA-N
|
| InChi Code |
InChI=1S/C59H84N18O14.C2H4O2/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38;1-2(3)4/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90);1H3,(H,3,4)/t38-,39-,40-,41-,42-,43-,44-,45+,46-;/m0./s1
|
| Chemical Name |
acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
|
| Synonyms |
Goserelin Acetate; ICI-118630; ICI118630; ICI 118630; brand name: Zoladex
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ~100 mg/mL (~75.2 mM)
DMSO: ≥ 28 mg/mL (~21.1 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (1.56 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (1.56 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: 2.08 mg/mL (1.56 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (37.61 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7522 mL | 3.7608 mL | 7.5217 mL | |
| 5 mM | 0.1504 mL | 0.7522 mL | 1.5043 mL | |
| 10 mM | 0.0752 mL | 0.3761 mL | 0.7522 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05694819 | Active Recruiting |
Other: Darolutamide Drug: Goserelin |
Salivary Gland Cancer | National Cancer Center Hospital East |
April 17, 2020 | Phase 2 |
| NCT00430183 | Active Recruiting |
Drug: docetaxel Drug: LHRH agonist |
Prostate Cancer | Alliance for Clinical Trials n Oncology |
May 8, 2007 | Phase 3 |
| NCT03423199 | Active Recruiting |
Drug: Palbociclib Drug: Goserelin |
Breast Neoplasms | National Cancer Center, Japan | February 9, 2018 | Phase 3 |
| NCT02430480 | Active Recruiting |
Drug: Goserelin Drug: Enzalutamide |
Prostate Cancer | National Cancer Institute (NCI) |
June 3, 2015 | Phase 2 |
| NCT03822468 | Active Recruiting |
Drug: Goserelin Drug: Ribociclib |
Breast Cancer | Novartis Pharmaceuticals | June 11, 2019 | Phase 2 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
